Provided by Tiger Fintech (Singapore) Pte. Ltd.

PolyPid Ltd.

2.91
+0.05501.93%
Volume:12.72K
Turnover:37.20K
Market Cap:29.60M
PE:-0.59
High:3.00
Open:2.89
Low:2.86
Close:2.85
Loading ...

PolyPid Ltd expected to post a loss of 80 cents a share - Earnings Preview

Reuters
·
12 May

PolyPid management to meet with Craig-Hallum

TIPRANKS
·
02 May

PolyPid to Participate in The Citizens Life Sciences Conference

GlobeNewswire
·
22 Apr

PolyPid Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Apr

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire
·
19 Mar

PolyPid’s Promising Outlook: Buy Rating Affirmed Amidst SHIELD II Trial Progress and Strategic FDA Engagement

TIPRANKS
·
12 Mar

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

GlobeNewswire
·
11 Mar

PolyPid to Participate in the 37th Annual ROTH Conference

GlobeNewswire
·
03 Mar

PolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs

GuruFocus.com
·
13 Feb

PolyPid (PYPD) Gets a Buy from JMP Securities

TIPRANKS
·
13 Feb

BUZZ-PolyPid falls on wider-than-expected quarterly loss

Reuters
·
13 Feb

PolyPid Ltd reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Feb

PolyPid Updates: New Board Appointment and SHIELD II Trial Progress

TIPRANKS
·
12 Feb

PolyPid Q4 2024 GAAP EPS $(1.13) Misses $(0.82) Estimate; Cash $15.6M

Benzinga
·
12 Feb

PolyPid Ltd Qtrly EPS $-1.13

THOMSON REUTERS
·
12 Feb

PolyPid Ltd expected to post a loss of 88 cents a share - Earnings Preview

Reuters
·
10 Feb

PolyPid Ltd Files for Resale of up to 11.23 Mln Ordinary Shares by the Selling Shareholders - SEC Filing

THOMSON REUTERS
·
22 Jan

PolyPid Regains Nasdaq Compliance with Private Placement Boost

TIPRANKS
·
18 Jan

HC Wainwright Adjusts Price Target on PolyPid to $11 From $14, Keeps Buy Rating

MT Newswires Live
·
27 Dec 2024

PolyPid Advances Phase 3 Trial and Secures Financing

TIPRANKS
·
26 Dec 2024